Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: Data from the AWARD phase III clinical trial programme

Diabetes, Obesity and Metabolism

Volumn 18, Issue 4, 2016, Pages 419-424

  Yu, M ^a   Van Brunt, K ^a   Varnado, O J ^a   Boye, K S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

GLP 1 receptor agonist; Patient reported outcomes; Type 2 diabetes

Indexed keywords

DULAGLUTIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ARTICLE; BODY WEIGHT; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; ADVERSE EFFECTS; AGED; AGONISTS; ANALOGS AND DERIVATIVES; BLOOD; BODY MASS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; HYPERGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; OVERWEIGHT; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SUBCUTANEOUS DRUG ADMINISTRATION; WEIGHT LOSS PROGRAM;

AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OVERWEIGHT; QUALITY OF LIFE; RECOMBINANT FUSION PROTEINS; SELF REPORT; WEIGHT LOSS; WEIGHT REDUCTION PROGRAMS;

EID: 84959871701     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12624     Document Type: Article

References (19)

1. Barrington P, Chien JY, Showalter HD et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 426-433.
2. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011; 13: 434-438.
3. Dungan KM, Povedano ST, Forst T et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384: 1349-1357.
4. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37: 2149-2158.
5. Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014; 37: 2168-2176.
6. Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab 2015; 17: 849-858.
7. Wysham C, Blevins T, Arakaki R et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37: 2159-2167.
8. Blonde L, Jendle J, Gross J et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015; 385: 2057-2066.
9. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015; 38: 2241-2249.
10. Hayes RP, DeLozier AM. Reliability, validity, and responsiveness of the impact of weight on self-perceptions questionnaire (IW-SP) in individuals with type 2 diabetes and obesity. Diabetes Technol Ther 2015; 17: 210-214.
11. Hayes RP, Schultz EM, Naegeli AN, Curtis BH. Test-retest, responsiveness, and minimal important change of the ability to perform physical activities of daily living questionnaire in individuals with type 2 diabetes and obesity. Diabetes Technol Ther 2012; 14: 1118-1125.
12. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res 2001; 9: 102-111.
13. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
14. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108.
15. Reaney M, Yu M, Lakshmanan M, Pechtner V, van Brunt K. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab 2015; 17: 896-903.
16. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 1994; 11: 253-261.
17. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987; 10: 617-621.
18. Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence 2012; 6: 39-48.
19. Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009; 26: 722-728.